Prevalence of H. pylori infection and atrophic gastritis among symptomatic and dyspeptic adults in Kazakhstan. A hospital-based screening study using a panel of serum biomarkers

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4595-4602

  Benberin, Valery ^a   Bektayeva, Roza ^b   Karabayeva, Raushan ^a   Lebedev, Aleksandr ^a   Akemeyeva, Kenzhekhan ^a   Paloheimo, Lea ^c   Syrjänen, Kari ^c,d,e  

^a Hosp of the Medical Center of the President's Affairs Administration of the Republic of Kazakhstan   (Kazakhstan)

^b ASTANA MEDICAL UNIVERSITY   (Kazakhstan)

^c Biohit HealthCare Oyj   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

Achlorhydria; Antrum; Atrophic gastritis; Biomarker panel; Blood test; Corpus; Gastric cancer; Gastrin 17; Helicobacter pylori; Pepsinogens; Risk factors

Indexed keywords

BACTERIUM ANTIBODY; BIOLOGICAL MARKER; GASTRIN 17; IMMUNOGLOBULIN G ANTIBODY; PEPSINOGEN I; PEPSINOGEN II;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATROPHIC GASTRITIS; BLOATING; BLOOD SAMPLING; CANCER RISK; DYSPEPSIA; EPIGASTRIC PAIN; FEMALE; HELICOBACTER INFECTION; HUMAN; KAZAKHSTAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; STOMACH ANTRUM; STOMACH CANCER; VOMITING; YOUNG ADULT;

ACHLORHYDRIA; ANTRUM; ATROPHIC GASTRITIS; BIOMARKER PANEL; BLOOD TEST; CORPUS; GASTRIC CANCER; GASTRIN-17; HELICOBACTER PYLORI; PEPSINOGENS; RISK FACTORS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BACTERIAL; BIOLOGICAL MARKERS; DYSPEPSIA; FEMALE; GASTRINS; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; KAZAKHSTAN; MALE; MIDDLE AGED; PEPSINOGEN A; PEPSINOGEN C; PHENOTYPE; PREVALENCE; SEX DISTRIBUTION; YOUNG ADULT;

EID: 84891364676     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Talley NJ, Zinsmeister AR, Schleck CD and Melton III LJ: Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterol 102: 1259-1268, 1992.
2. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ and Thompson WG: U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci 38: 1569-1580, 1993.
3. Hansen JM, Bytzer P, Schaffalitzky D and Muckadell OB: Management of dyspeptic patients in primary care. Value of the unaided clinical diagnosis and of dyspepsia subgrouping. Scand J Gastroenterol 33: 799-805, 1998.
4. Heikkinen M, Pikkarainen P, Takala J and Julkunen R: General practitioners' approach to dyspepsia. Survey of consultation frequencies, treatment, and investigations. Scand J Gastroenterol 31: 648-653, 1996.
5. Majumdar SR, Soumerai SB, Farraye FA, Lee M, Kemp JA and Henning JM: Chronic acid-related disorders are common and under investigated. Am J Gastroenterol 98: 2409-2414, 2003.
6. Nebel OT, Fornes MF and Castell DO: Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Digest Dis 21: 953-956, 1976.
7. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM and Kuipers EJ: European Helicobacter Study Group. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report. Gut 61: 646-664, 2012.
8. Sipponen P, Kekki M, Haapakoski J, Ihamäki T and Siurala M: Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 35: 173-177, 1985.
9. Israel DA and Peek RM: Review article: pathogenesis of Helicobacter pylori-induced gastric inflammation. Aliment Pharmacol Ther 15: 1271-1290, 2001.
10. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA and Jellum E: Helicobacter pylori infection and gastric lymphoma. N Engl J Med 330: 1267-1271, 1994.
11. Khulusi S, Mendall MA, Patel P, Levy J, Badve S and Northfield TC: Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects. Gut 37: 319-324, 1995.
12. International Agency for Research on Cancer, World Health Organization. Schistosomiasis, liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to human. Monogr Eval Carcinog Risks Hum 61: 218-220, 1994.
13. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S and Yamakido M: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 829-832, 2001.
14. Valle J, Kekki M, Sipponen P, Ihamäki T and Siurala M: Longterm course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol 31: 546-550, 1996.
15. Kuipers EJ, Uyterlinde AM, Peña AS, Roosendaal R, Pals G and Nelis GF: Long-term sequelae of Helicobacter pylori gastritis. Lancet 345: 1525-1528, 1995.
16. Correa P, Haenszel W, Cuello C, Zavala D, Fontham E and Zarama G: Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 50: 4737-4740, 1990.
17. Filipe MI, Munoz N, Matko I, Kato I, Pompe-Kirn V and Jutersek A: Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 57: 324-329, 1994.
18. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M and Nakamura H: Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 109: 138-143, 2004.
19. Correa P: A human model of gastric carcinogenesis. Cancer Res 48: 3554-3560, 1988.
20. Correa P: The epidemiology of gastric cancer. World J Surg 15: 228-234, 1991.
21. Correa P: Human gastric carcinogenesis:a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52: 6735-6740, 1992.
22. Weck MN, Stegmaier C, Rothenbacher D and Brenner H: Epidemiology of chronic atrophic gastritis: population-based study among 9444 older adults from Germany. Aliment Pharmacol Ther 26: 879-887, 2007.
23. Lomba-Viana R, Dinis-Ribeiro M, Fonseca F, Vieira AS, Bento MJ and Lomba-Viana H: Serum pepsinogen test for early detection of gastric cancer in a European country. Eur J Gastroenterol Hepatol 24: 37-41, 2012.
24. Bornschein J, Selgrad M, Wex T, Kuester D and Malfertheiner P: Serological assessment of gastric mucosal atrophy in gastric cancer. BMC Gastroenterol 201212:10. doi: 10.1186/1471-230X-12-10.
25. Germaná B, Di Mario F, Cavallaro LG, Moussa AM, Lecis P, Liatoupolou S, Comparato G, Carloni C, Bertiato G, Battiestel M, Papa N, Aragona G, Cavestro GM, Iori V, Merli R, Bertolini S, Caruana P and Franzé A: Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care. Dig Liver Dis 37: 501-508, 2005.
26. Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, Furihata C, Matsushima T and Takahashi K: Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn 22: 133-141, 1987.
27. Samloff IM, Varis K, Ihamaki T, Siurala M and Rotter JI: Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterol 83: 204-209, 1982.
28. Korstanje A, den Hartog G, Biemond I and Lamers CB: The serological gastric biopsy: a non-endoscopical diagnostic approach in management of the dyspeptic patient: significance for primary care based on a survey of the literature. Scand J Gastroenterol Suppl 236: 22-26, 2002.
29. Oksanen A, Sipponen P, Miettinen A, Sarna S and Rautelin H: Evaluation of bood tests to normal gastric mucosa. Scand J Gastroenterol 35: 791-795, 2000.
30. Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, and The Helsinki Gastritis Study Group: Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Scand J Gastroenterol 35: 950-956, 2000.
31. Miki K: Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 9: 245-253, 2006.
32. Agréus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, Mahachai V, Yaron N, van Oijen M, Perez Perez G, Rugge M, Ronkainen J, Salaspuro M, Sipponen P, Sugano K and Sung J: Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 47: 136-147, 2012.
33. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC: CancerBase No. 9. http://globocan.iarc.fr (Accessed August 14, 2013).
34. Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H and Talley NJ: Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 43: 1448-1455, 2008.
35. Telaranta-Keerie A, Kara R, Paloheimo L, Härkönen M and Sipponen P: Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints. Scand J Gastroenterol 45: 1036-1041, 2010.
36. Dixon MF, Genta RM, Yardley JH and Correa P: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20: 1161-1181, 1996.
37. Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M and Kurihara M: Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 11: 141-147, 2004.
38. Varis K and Isokoski M: Screening of type A gastritis. Ann Clin Res 13: 133-138, 1981.
39. Sipponen P, Valle J, Varis K, Kekki M, Ihamäki T and Siurala M: Fasting levels of serum gastrin in different functional and morphologic states of the antrofundal mucosa. An analysis of 860 subjects. Scand J Gastroenterol 25: 513-519, 1990.
40. Varis K, Kekki M, Härkönen M, Sipponen P and Samloff IM: Serum pepsinogen I and serum gastrin in the screening of atrophic pangastritis with high risk of gastric cancer. Scand J Gastroenterol 186: 117-123, 1991.
41. Sipponen P, Ranta P, Helske T, Kääriäinen I, Mäki T and Linnala A. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. Scand J Gastroenterol 37: 785-791, 2002.